Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.

Al-Batran, S-E

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Apr 2016 - 673-9 p. digital

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1569-8041

10.1093/annonc/mdv625 doi


Adenocarcinoma--drug therapy
Adult
Aged
Antibodies, Monoclonal--administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
Disease-Free Survival
Esophageal Neoplasms--drug therapy
Esophagogastric Junction--drug effects
Female
Humans
Male
Middle Aged
Paclitaxel--administration & dosage
Quality of Life
Treatment Outcome
Ramucirumab